Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human (FIH), Phase I/II, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of Zn-Telomir Administered Orally as Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)

NCT07581314 is registered in ClinicalTrials.gov with Telomir Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07581314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07581314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human (FIH), Phase I/II, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of Zn-Telomir Administered Orally as Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
Lead sponsor
Telomir Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
November 30, 2027
Enrollment
76 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced triple-negative breast cancer, metastatic triple-negative breast cancer, triple-negative breast cancer (tnbc)